Oxaliplatin-induced Pulmonary Fibrosis: Two Case Reports
À¯Ãá±Ù, Á¤ÀºÁÖ, ±è°¹Ì, ±è¼ö¶õ, Ȳ´ë¿ë,
¼Ò¼Ó »ó¼¼Á¤º¸
À¯Ãá±Ù ( Ryu Chun-Geun )
°Ç±¹´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ¿Ü°úÇб³½Ç
Á¤ÀºÁÖ ( Jung Eun-Joo )
°Ç±¹´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ¿Ü°úÇб³½Ç
±è°¹Ì ( Kim Gang-Mi )
°Ç±¹´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
±è¼ö¶õ ( Kim Su-Ran )
°Ç±¹´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
Ȳ´ë¿ë ( Hwang Dae-Yong )
°Ç±¹´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
KMID : 0356720110270050266
Abstract
Oxaliplatin with infusional 5-fluorouracil plus leucovorin (FOLFOX regimen) is the one of the standard chemotherapy regimens for treating a colorectal carcinoma. The most common side effects include neutropenia, diarrhea, vomiting and peripheral neuropathy, and these are moderate and manageable. However, pulmonary toxicity is rarely reported to be associated with the FOLFOX regimen. Moreover, there is no established guideline for the management of this side effect. Here, along with a literature review, we report two cases of rapidly developing pulmonary fibrosis related to the use of the FOLFOX regimen in patients with colorectal carcinomas.
Å°¿öµå
Oxaliplatin;Toxicity;Pulmonary fibrosis.
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸